REVELATION BIOSCIENCES, INC.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
REVB$4.11+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Operations
| Year EndedDecember 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| Research and development | $4,063,857 | $3,548,996 |
| General and administrative | 5,006,957 | 4,426,113 |
| Total operating expenses | 9,070,814 | 7,975,109 |
| Loss from operations | (9,070,814) | (7,975,109) |
| Other income (expense): | ||
| Change in fair value of warrant liability | 2,158 | 81,441 |
| Other income (expense), net | 155,007 | (7,144,868) |
| Total other income (expense), net | 157,165 | (7,063,427) |
| Net loss | $(8,913,649) | $(15,038,536) |
| Deemed dividends | (5,951,528) | — |
| Net loss attributable to common stockholders | (14,865,177) | (15,038,536) |
| Net loss per share, basic and diluted | $(23.95) | $(1,052.16) |
| Weighted-average shares used to compute net loss per share, basic and diluted | 620,785 | 14,293 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.